Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Overview of Study Design: This is a phase 1, multicenter, open-label, multiple-dose,
dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK),
and antitumor activity of TAK-960 in patients with advanced nonhematologic malignancies. This
study will be the first to administer TAK-960 to humans. The patient population will consist
of adults with a nonhematologic malignancy for which standard treatment is no longer
effective or does not offer curative or life-prolonging potential, or for which no standard
treatment is available.